Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia

  • Respiratory Infections (F Arnold, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Here, we review current available literature regarding the effect of prior antibiotic treatment on outcomes of children hospitalized for community-acquired pneumonia (CAP). To date, no prospective trial has reported information regarding morbidity or mortality in this group of patients. Retrospective studies have provided evidence for the advantage of treatment with broad-spectrum antibiotics in children who failed prior antibiotic therapy. We discuss the changing epidemiology of CAP in the post PCV13 and Hib vaccines era and its relevance to the outcome of pediatric patients hospitalized for CAP. Current studies still report Streptococcus pneumoniae as the most common typical bacterial causative agent in pediatric CAP. However, in children who fail to respond to guideline directed antibiotic therapy, a non-pneumococcal, possibly one of several β-lactam resistant causative bacterial agents should be considered thus clarifying the advantage for broad-spectrum empirical antibiotic treatment in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–16. Global epidemilogical data regarding childhood pneumonia.

    Article  PubMed  Google Scholar 

  2. Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204–13.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–45. Updated data on pediatric community aquired pneumonia hospitalization in the U.S..

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701–7.

    Article  PubMed  Google Scholar 

  5. Lahti E, Peltola V, Waris M, Virkki R, Rantakokko-Jalava K, Jalava J, et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax. 2009;64(3):252–7.

    Article  PubMed  CAS  Google Scholar 

  6. Blaschke AJ, Heyrend C, Byington CL, Obando I, Vazquez-Barba I, Doby EH, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30(4):289–94.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Juven T, Mertsola J, Toikka P, Virkki R, Leinonen M, Ruuskanen O. Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr Infect Dis J. 2001;20(11):1028–33.

    Article  PubMed  CAS  Google Scholar 

  8. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293–8.

    Article  PubMed  CAS  Google Scholar 

  9. Claesson BA, Lagergard T, Trollfors B. Antibody response to outer membrane of noncapsulated Haemophilus influenzae isolated from the nasopharynx of children with pneumonia. Pediatr Infect Dis J. 1991;10(2):104–8.

    Article  PubMed  CAS  Google Scholar 

  10. Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J. 1989;8(3):143–8.

    PubMed  CAS  Google Scholar 

  11. Gendrel D, Raymond J, Moulin F, Iniguez JL, Ravilly S, Habib F, et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol. 1997;16(5):388–91.

    Article  CAS  Google Scholar 

  12. Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013;6, CD004874. Treatment guidelines for pediatric community aquired pneumonia.

    PubMed  Google Scholar 

  13. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2:ii1–23. Treatment guidelines for pediatric community aquired pneumonia.

    Article  PubMed  Google Scholar 

  14. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(7):e25–76. Treatment guidelines for pediatric community aquired pneumonia.

    Article  Google Scholar 

  15. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;44(2):159–77.

    Article  Google Scholar 

  16. FDA. FDA approves pneumococcal disease vaccine with broader protection 2010 [updated 04/24/2013 cited 2015 14 June]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201758.htm.

  17. Advisory Committee on Immunization P. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2000 Oct 6;49(RR-9):1–35. PubMed.

  18. Nuorti JP, Whitney CG, Centers for Disease C, Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2010 Dec 10;59(RR-11):1–18. PubMed

  19. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–46.

    Article  PubMed  Google Scholar 

  20. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.

    Article  PubMed  Google Scholar 

  21. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179–86.

    Article  PubMed  CAS  Google Scholar 

  22. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309–10.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet. 2000;356(9237):1210–1.

    Article  PubMed  CAS  Google Scholar 

  24. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A. 1997;94(12):6571–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;59(8):1066–73.

    Article  Google Scholar 

  26. Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceno R, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33(6):637–42.

    Article  PubMed  Google Scholar 

  27. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–94.

    Article  PubMed  Google Scholar 

  28. Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(6):629.

    Article  PubMed  Google Scholar 

  29. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455–63.

    Article  PubMed  CAS  Google Scholar 

  30. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. Journal Infect Dis. 2014;210(7):1001–11.

    Article  Google Scholar 

  31. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.

    Article  PubMed  CAS  Google Scholar 

  32. Sinaniotis CA, Sinaniotis AC. Community-acquired pneumonia in children. Curr Opin Pulm Med. 2005;11(3):218–25.

    Article  PubMed  Google Scholar 

  33. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2009;48(11):1596–600.

    Article  CAS  Google Scholar 

  34. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010;29(11):1043–6.

    Article  PubMed  Google Scholar 

  35. Dagan R, Hoberman A, Johnson C, Leibovitz EL, Arguedas A, Rose FV, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20(9):829–37.

    Article  PubMed  CAS  Google Scholar 

  36. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14(10):885–90.

    Article  PubMed  CAS  Google Scholar 

  37. Aurangzeb B, Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children. J Coll Physicians Surg Pak: JCPSP. 2003;13(12):704–7.

    PubMed  Google Scholar 

  38. Vuori-Holopainen E, Peltola H, Kallio MJ, Group S-TS. Narrow- versus broad-spectrum parenteral anatimicrobials against common infections of childhood: a prospective and randomised comparison between penicillin and cefuroxime. Eur J Pediatr. 2000;159(12):878–84.

    Article  PubMed  CAS  Google Scholar 

  39. Klein M. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. Pediatr Infect Dis J. 1995;14(4 Suppl):S19–22.

    Article  PubMed  CAS  Google Scholar 

  40. Amir J, Harel L, Eidlitz-Markus T, Varsano I. Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. Clin Pediatr. 1996;35(12):629–33.

    Article  CAS  Google Scholar 

  41. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–65.

    Article  PubMed  CAS  Google Scholar 

  42. Nathwani D, Williams F, Winter J, Winter J, Ogston S, Davey P. Use of indicators to evaluate the quality of community-acquired pneumonia management. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2002;34(3):318–23.

    Google Scholar 

  43. Levy G, Perez M, Rodriguez B, Hernandez Voth A, Perez J, Gnoni M, et al. Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela. Arch Bronconeumol. 2015;51(4):163–8.

    Article  PubMed  Google Scholar 

  44. Chenoweth CE, Saint S, Martinez F, Lynch 3rd JP, Fendrick AM. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia. Mayo Clin Proc. 2000;75(11):1161–8.

    Article  PubMed  CAS  Google Scholar 

  45. De Schutter I, De Wachter E, Crokaert F, Verhaegen J, Soetens O, Pierard D, et al. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: identification of nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(12):1437–44.

    Article  Google Scholar 

  46. Van Eldere J, Slack MP, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14(12):1281–92.

    Article  PubMed  CAS  Google Scholar 

  47. Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay ME, et al. Invasive Haemophilus influenzae disease, Europe, 1996–2006. Emerg Infect Dis. 2010;16(3):455–63. Review regarding invasive haemophilus influenza disease in europe.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Giufre M, Cardines R, Caporali MG, Accogli M, D’Ancona F, Cerquetti M. Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine. 2011;29(22):3857–62.

    Article  PubMed  Google Scholar 

  49. MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease—United States, 1989–2008. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(12):1230–6.

    Article  Google Scholar 

  50. Pirez MC, Algorta G, Chamorro F, Romero C, Varela A, Cedres A, et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay. Pediatr Infect Dis J. 2014;33(7):753–9.

    Article  PubMed  Google Scholar 

  51. Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;58(7):918–24.

    Article  CAS  Google Scholar 

  52. Deeks SL, Palacio R, Ruvinsky R, Kertesz DA, Hortal M, Rossi A, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics. 1999;103(2):409–13.

    Article  PubMed  CAS  Google Scholar 

  53. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents. 2007;30 Suppl 2:S135–8.

    Article  PubMed  CAS  Google Scholar 

  54. Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Doern GV, Group GS. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP surveillance program. Int J Antimicrob Agents. 2005;25(2):148–56.

    Article  PubMed  CAS  Google Scholar 

  55. Cohen R, Bingen E, Levy C, Benani M, Thollot F, Klink Z, et al. Antibiotic resistance of pneumococci and H. influenzae isolated from the nasopharyngeal flora of children with acute otitis media between 2006 and 2010. Arch Pediatrie: Organe Off Soc Fr Pediatrie. 2011;18(8):926–31. PubMed Resistance aux antibiotiques des pneumocoques et H. influenzae isoles de la flore rhinopharyngee d’enfants presentant une otite moyenne aigue entre 2006 et 2010.

    Article  CAS  Google Scholar 

  56. Resman F, Ristovski M, Forsgren A, Kaijser B, Kronvall G, Medstrand P, et al. Increase of beta-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother. 2012;56(8):4408–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Sill ML, Tsang RS. Antibiotic susceptibility of invasive Haemophilus influenzae strains in Canada. Antimicrob Agents Chemother. 2008;52(4):1551–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, et al. Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother. 2007;51(11):3969–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Garcia-Cobos S, Campos J, Lazaro E, Roman F, Cercenado E, Garcia-Rey C, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother. 2007;51(7):2564–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Queen MA, Myers AL, Hall M, Shah SS, Williams DJ, Auger KA, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014;133(1):e23–9.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Williams DJ, Hall M, Shah SS, Parikh K, Tyler A, Neuman MI, et al. Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia. Pediatrics. 2013;132(5):e1141–8.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Emery DP, Milne T, Gilchrist CA, Gibbons MJ, Robinson E, Coster GD, et al. The impact of primary care on emergency department presentation and hospital admission with pneumonia: a case-control study of preschool-aged children. NPJ Primary Care Respir Med. 2015;25:14113.

    Article  Google Scholar 

  63. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008;371(9606):49–56.

    Article  PubMed  CAS  Google Scholar 

  64. Breuer O, Blich O, Cohen-Cymberknoh M, Averbuch D, Kharasch S, Shoseyov D, et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015;50(5):495–502. The only current research evaluating the outcome of community aquired pneumonia in children with prior antibiotic therapy.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    Eran Lavi & Oded Breuer

  2. Pediatric Pulmonology Unit, Hadassah-Hebrew University Medical Center, 91120, Jerusalem, Israel

    Oded Breuer

Authors
  1. Eran Lavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oded Breuer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oded Breuer.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Respiratory Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lavi, E., Breuer, O. The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia. Curr Infect Dis Rep 18, 3 (2016). https://doi.org/10.1007/s11908-015-0509-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-015-0509-2

Keywords

Search

Navigation